ACCELERATE: Evacetrapib’s clinical failure sinks lipid-drug class
CHICAGO – A class of cholesterol drugs once considered a potentially very promising approach to beneficially reset lipid levels instead produced its third flameout in a pivotal clinical endpoints...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news
More News: Cholesterol | Endocrinology